Nuvalent
alk patient journey illustrative image of majority are advanced metastatic at diagnosis nee of care sales sales and are approved line agnostic was designed to address single mutations that resistance to and no clear standard of care patients may consider clinical trials or chemotherapy i key limitations single resistance mutations observed in of patients progressing on or brain penetrance present with brain metastases at diagnosis will develop brain metastases overall compound resistance activity no approved therapies have demonstrated activity after sequential to mutations observed in of patients progressing on sequential to treatment limiting off target adverse events adverse events associated with inhibition observed in of patients receiving sources chia sales and forecasts accessed guidelines for version jack cancer res cancer precis shaw a lancet package inserts cocco nat rev shaw a nature cancer | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
13 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
alk patient journey illustrative image of majority are advanced metastatic at diagnosis standard of care sales sales and are approved line agnostic was designed to address single mutations that resistance to and no clear standard of care patients may consider clinical trials or chemotherapy i key limitations single resistance compound resistance activity mutations mutations observed in of patients observed in of patients progressing on or brain penetrance present with brain metastases at diagnosis will develop brain metastases overall progressing on sequential to treatment limiting off target adverse events adverse events associated with inhibition observed in of patients receiving no approved therapies have demonstrated activity after sequential to sources chia year end earnings reports and guidelines for version shaw a jack cancer res cancer precis lancet package inserts cocco nat rev shaw a nature cancer | Nuvalent
Investor Presentation
February 2024
alk patient journey illustrative image of majority are advanced metastatic at diagnosis standard of care sales sales and are approved line agnostic was designed to address single mutations that resistance to and no clear standard of care patients may consider clinical trials or chemotherapy i key limitations single resistance mutations observed in of patients progressing on or brain penetrance present with brain metastases at diagnosis will develop brain metastases overall compound resistance activity no approved therapies have demonstrated activity after sequential to mutations observed in of patients progressing on sequential to treatment limiting off target adverse events adverse events associated with inhibition observed in of patients receiving sources chia year end earnings reports and guidelines for version shaw a lancet package inserts cocco nat rev shaw a nature cancer jack cancer res cancer precis | Nuvalent
Investor Presentation
January 2024
alk patient journey of majority are advanced metastatic at diagnosis nee of care sales sales and are approved line agnostic was designed to address single mutations that resistance to and no clear standard of care patients may consider clinical trials or chemotherapy i key limitations single resistance mutations observed in of patients progressing on or brain penetrance present with brain metastases at diagnosis will develop brain metastases overall compound resistance activity no approved therapies have demonstrated activity after sequential to mutations observed in of patients progressing on sequential to treatment limiting off target adverse events adverse events associated with inhibition observed in of patients receiving sources chia sales and forecasts accessed guidelines for version jack cancer res cancer precis shaw a lancet package inserts cocco nat rev shaw a nature cancer illustrative image | Nuvalent
Related slides by other companies
AstraZeneca
Investor Day
June 2021
changing treatment expectations in continuing to push the boundaries of science and patient care | AstraZeneca
Imara
Mergers and Acquisitions
October 2022
our strategy and initial positioning in an evolving market to | Imara
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io